ProMetic Life Sciences Inc. (PLI) Receives Average Rating of “Buy” from Brokerages

ProMetic Life Sciences Inc. (TSE:PLI) has been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is C$3.50.

Several brokerages recently weighed in on PLI. National Bank Financial cut their price objective on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th.

Shares of ProMetic Life Sciences (PLI) traded up C$0.06 on Friday, reaching C$1.76. 1,148,900 shares of the company traded hands, compared to its average volume of 1,130,000. The company has a market capitalization of $1,250.00, a price-to-earnings ratio of -10.35 and a beta of 2.39. ProMetic Life Sciences has a 52-week low of C$1.12 and a 52-week high of C$2.64.

ProMetic Life Sciences (TSE:PLI) last issued its quarterly earnings data on Monday, November 13th. The company reported C($0.01) earnings per share for the quarter. ProMetic Life Sciences had a negative net margin of 73.85% and a negative return on equity of 48.83%.

In other news, Director Steven J. Burton sold 98,075 shares of ProMetic Life Sciences stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of C$1.54, for a total value of C$151,035.50.

ILLEGAL ACTIVITY WARNING: “ProMetic Life Sciences Inc. (PLI) Receives Average Rating of “Buy” from Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/27/prometic-life-sciences-inc-pli-receives-average-rating-of-buy-from-brokerages.html.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply